 Antibodies, Viral
"Antibodies, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins produced in response to VIRAL ANTIGENS.
| Descriptor ID |
D000914
|
| MeSH Number(s) |
D12.776.124.486.485.114.254 D12.776.124.790.651.114.254 D12.776.377.715.548.114.254
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Viral".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Viral".
This graph shows the total number of publications written about "Antibodies, Viral" by people in this website by year, and whether "Antibodies, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 1 | 2 | 3 | | 1981 | 1 | 1 | 2 | | 1982 | 1 | 1 | 2 | | 1983 | 1 | 2 | 3 | | 1985 | 2 | 4 | 6 | | 1986 | 2 | 2 | 4 | | 1987 | 3 | 2 | 5 | | 1988 | 3 | 1 | 4 | | 1989 | 1 | 1 | 2 | | 1990 | 2 | 1 | 3 | | 1991 | 2 | 1 | 3 | | 1992 | 2 | 0 | 2 | | 1993 | 0 | 2 | 2 | | 1994 | 0 | 1 | 1 | | 1995 | 2 | 2 | 4 | | 1996 | 1 | 3 | 4 | | 1997 | 1 | 1 | 2 | | 1998 | 0 | 1 | 1 | | 1999 | 3 | 2 | 5 | | 2000 | 2 | 3 | 5 | | 2001 | 0 | 4 | 4 | | 2002 | 3 | 2 | 5 | | 2003 | 1 | 5 | 6 | | 2005 | 1 | 4 | 5 | | 2006 | 0 | 4 | 4 | | 2007 | 2 | 4 | 6 | | 2008 | 1 | 6 | 7 | | 2009 | 4 | 2 | 6 | | 2010 | 2 | 0 | 2 | | 2011 | 4 | 8 | 12 | | 2012 | 4 | 3 | 7 | | 2013 | 5 | 2 | 7 | | 2014 | 2 | 4 | 6 | | 2015 | 4 | 4 | 8 | | 2016 | 5 | 1 | 6 | | 2017 | 1 | 1 | 2 | | 2018 | 3 | 1 | 4 | | 2019 | 1 | 2 | 3 | | 2020 | 5 | 7 | 12 | | 2021 | 9 | 12 | 21 | | 2022 | 0 | 5 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Viral" by people in Profiles.
-
Sancilio A, Schrock JM, Demonbreun AR, D'Aquila RT, Mustanski B, Vaught LA, Reiser NL, Velez MP, Hsieh RR, Ryan DT, Saber R, McNally EM, McDade TW. COVID-19 symptom severity predicts neutralizing antibody activity in a community-based serological study. Sci Rep. 2022 07 18; 12(1):12269.
-
Self WH, Wheeler AP, Stewart TG, Schrager H, Mallada J, Thomas CB, Cataldo VD, O'Neal HR, Shapiro NI, Higgins C, Ginde AA, Chauhan L, Johnson NJ, Henning DJ, Jaiswal SJ, Mammen MJ, Harris ES, Pannu SR, Laguio-Vila M, El Atrouni W, de Wit M, Hoda D, Cohn CS, McWilliams C, Shanholtz C, Jones AE, Raval JS, Mucha S, Ipe TS, Qiao X, Schrantz SJ, Shenoy A, Fremont RD, Brady EJ, Carnahan RH, Chappell JD, Crowe JE, Denison MR, Gilchuk P, Stevens LJ, Sutton RE, Thomsen I, Yoder SM, Bistran-Hall AJ, Casey JD, Lindsell CJ, Wang L, Pulley JM, Rhoads JP, Bernard GR, Rice TW. Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial. Chest. 2022 11; 162(5):982-994.
-
Hernandez-Davies JE, Dollinger EP, Pone EJ, Felgner J, Liang L, Strohmeier S, Jan S, Albin TJ, Jain A, Nakajima R, Jasinskas A, Krammer F, Esser-Kahn A, Felgner PL, Nie Q, Davies DH. Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants. Sci Rep. 2022 06 02; 12(1):9198.
-
Rouhani SJ, Yu J, Olson D, Zha Y, Pezeshk A, Cabanov A, Pyzer AR, Trujillo J, Derman BA, O'Donnell P, Jakubowiak A, Kindler HL, Bestvina C, Gajewski TF. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6).
-
Tang J, Novak T, Hecker J, Grubbs G, Zahra FT, Bellusci L, Pourhashemi S, Chou J, Moffitt K, Halasa NB, Schwartz SP, Walker TC, Tarquinio KM, Zinter MS, Staat MA, Gertz SJ, Cvijanovich NZ, Schuster JE, Loftis LL, Coates BM, Mack EH, Irby K, Fitzgerald JC, Rowan CM, Kong M, Flori HR, Maddux AB, Shein SL, Crandall H, Hume JR, Hobbs CV, Tremoulet AH, Shimizu C, Burns JC, Chen SR, Moon HK, Lange C, Randolph AG, Khurana S. Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C. Nat Commun. 2022 05 27; 13(1):2979.
-
McGrath JJC, Li L, Wilson PC. Memory B cell diversity: insights for optimized vaccine design. Trends Immunol. 2022 05; 43(5):343-354.
-
Li L, Changrob S, Fu Y, Stovicek O, Guthmiller JJ, McGrath JJC, Dugan HL, Stamper CT, Zheng NY, Huang M, Wilson PC. Librator: a platform for the optimized analysis, design, and expression of mutable influenza viral antigens. Brief Bioinform. 2022 03 10; 23(2).
-
Dugan HL, Wilson PC. Teach 'em young: Influenza vaccines induce broadly neutralizing antibodies in children. Cell Rep Med. 2022 02 15; 3(2):100531.
-
Chan CW, Yi X, Lenza M, Baldwin AD, Jakalski J, Tesic V, Yeo KJ. Analytical and Clinical Evaluation of the Semiquantitative Elecsys Anti-SARS-CoV-2 Spike Protein Receptor Binding Domain Antibody Assay on the Roche cobas e602 Analyzer. Am J Clin Pathol. 2022 01 06; 157(1):109-118.
-
Guthmiller JJ, Han J, Utset HA, Li L, Lan LY, Henry C, Stamper CT, McMahon M, O'Dell G, Fernández-Quintero ML, Freyn AW, Amanat F, Stovicek O, Gentles L, Richey ST, de la Peña AT, Rosado V, Dugan HL, Zheng NY, Tepora ME, Bitar DJ, Changrob S, Strohmeier S, Huang M, García-Sastre A, Liedl KR, Bloom JD, Nachbagauer R, Palese P, Krammer F, Coughlan L, Ward AB, Wilson PC. Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature. 2022 02; 602(7896):314-320.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|